Claims
- 1. A compound of the formula ##STR21## or a physiologically acceptable salt or solvate thereof, wherein Q represents a 1- or 2-naphthalenyl group.
- 2. A compound according to claim 1 comprising 5-[1-hydroxy-2-[[6-[(2-naphthalenyl)ethoxy]hexyl]amino]ethyl]-1,3-benzenediol or a physiologically acceptable salt or solvate thereof.
- 3. A compound according to claim 2 in the form of its 4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylate] (2:1) salt.
- 4. A pharmaceutical composition which comprises an effective amount of at least one compound as defined in claim 1 or a physiologically acceptable salt or solvate thereof together with a physiologically acceptable carrier or excipient.
- 5. A method of therapy or prophylaxis of a disease associated with reversible airways obstruction in a patient, which comprises administering to said patient an effective amount to alleviate said disease of at least one compound as defined in claim 1 or a physiologically acceptable salt or solvate thereof.
- 6. A method of treating a patient suffering from premature labour, depression, congestive heart failure, an inflammatory or allergic skin disease, glaucoma or a condition in which there is an advantage in lowering gastric acidity which method comprises administering to said patient an effective amount to alleviate said condition of at least one compound as defined in claim 1 or a physiologically acceptable salt or solvate thereof.
- 7. A method according to claim 5, wherein the disease is associated with reversible airways obstruction is asthma or chronic bronchitis.
- 8. A method according to claim 6, wherein the method comprises treating a patient suffering from gastric or peptic ulceration.
Priority Claims (2)
Number |
Date |
Country |
Kind |
8726586 |
Nov 1987 |
GBX |
|
8821179 |
Sep 1988 |
GBX |
|
Parent Case Info
This is a divisional of co-pending application Ser. No. 07/270,945 filed Nov. 14, 1988, now allowed (U.S. Pat. No. 4,997,986).
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4010189 |
Smith |
Mar 1977 |
|
4558051 |
Sunshine et al. |
Dec 1985 |
|
4730008 |
Skidmore et al. |
Mar 1988 |
|
4997986 |
Mitchell et al. |
Mar 1991 |
|
Foreign Referenced Citations (15)
Number |
Date |
Country |
0162576 |
Nov 1985 |
EPX |
0220878 |
May 1987 |
EPX |
223410A |
May 1987 |
EPX |
286242A |
Dec 1988 |
EPX |
2164505 |
Aug 1972 |
DEX |
95908 |
Mar 1972 |
FRX |
1069411 |
May 1967 |
GBX |
1094461 |
Dec 1967 |
GBX |
1330188 |
Sep 1973 |
GBX |
1381184 |
Jan 1975 |
GBX |
2006772 |
May 1979 |
GBX |
2140800A |
Dec 1984 |
GBX |
2159151A |
Nov 1985 |
GBX |
2165542A |
Apr 1986 |
GBX |
2182548A |
May 1987 |
GBX |
Non-Patent Literature Citations (3)
Entry |
The Merck Index, tenth Ed., 1983, pp. 573-574 (entry relating to Fenoterol). |
Coleman et al., "Novel and Versatile Superfusion System", (1989), pp. 71-86. |
Boehringer Ingelheim Limited "Berotec", ABPI Data Sheet Compendium 1988-1989, p. 215 Fenoterol--3914 Fenoterol--p. 573. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
270945 |
Nov 1988 |
|